Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use OPFOLDA® safely and effectively. See full prescribing information for OPFOLDA. OPFOLDA (miglustat) capsules, for oral use Initial U.S. Approval: 2003
Medication labelWhy this: Advisory · dailymed-prescription
OPFOLDA is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).
- generic_name
- miglustat
- product_names
- miglustat
- ndc
- 71904-300, 71904-300-01, 71904-300-02, 71904-300-03
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en